Ranbaxy agrees North American products tie-up with Zenotech
The US division of Indian generics group Ranbaxy Laboratories has teamed up with fellow Indian company Zenotech Laboratories in an oncology products development and marketing deal forecast to achieve nearly $4bn in annual sales.
The US division of Indian generics group Ranbaxy Laboratories has teamed up with fellow Indian company Zenotech Laboratories in an oncology products development and marketing deal forecast to achieve nearly $4bn in annual sales.
Biotech group Zenotech, which specialises in generic injectables, will develop, submit for filing and manufacture a total of 11 oncology products which Ranbaxy Pharmaceuticals will manufacture as generic formulations in the US and Canada under its name. Ranbaxy estimates the combined sales of these products will be some $3.7bn.
Malvinder Singh, ceo and md of Ranbaxy Labora-tories, said the first products have been agreed between the two companies. "We anticipate a number of additional products materialising in the months ahead as a result of this mutually beneficial partnership."